Gait analysis in advanced Parkinson's disease--effect of levodopa and tolcapone.
OBJECTIVE
To determine the therapeutic effect of levodopa/benserazide and tolcapone on gait in patients with advanced Parkinson's disease.


METHODS
Instrumental gait analysis was performed in 38 out of 40 patients with wearing-off phenomenon during a randomized, double-blind, placebo-controlled trial of tolcapone.


RESULTS
Gait analysis disclosed a significant improvement by levodopa/benserazide in walking speed, stride length and the range of motion of hip, knee and ankle joints. At the end of the study, both the UPDRS motor scores during off-period and the percentage of off time improved significantly using tolcapone. However, gait analysis could not confirm this improvement. With respect to levodopa/benserazide effect, the reduction in rigidity correlated with improved angular excursion of the ankle, whereas the decreased bradykinesia correlated with improved stride length and angular excursion of the hip and knee joints.


CONCLUSIONS
The results of our gait analysis confirmed that in parkinsonian patients with fluctuating motor symptoms levodopa/benserazide, but not tolcapone, produced a substantial improvement.
Neurological Institute, Taipei Veterans General Hospital, Department of Neurology, National Yang-Ming University, Taiwan, Republic of China.
D E
DE
Shan
S J
SJ
Lee
L Y
LY
Chao
S I
SI
Yeh
D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001577:Benzophenones / Q000627:therapeutic use*; D001682:Biological Availability; D004311:Double-Blind Method; D005260:Female; D005684:Gait / Q000187:drug effects / Q000502:physiology*; D006207:Half-Life; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D009596:Nitrophenols; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology*; D000077867:Tolcapone
D000978:Antiparkinson Agents; D001577:Benzophenones; D009596:Nitrophenols; D007980:Levodopa; D000077867:Tolcapone